PCSK9 inhibitors and their role in high-risk patients in reducing LDL cholesterol levels: Alirocumab

Chanukya Dahagam, Aditya Goud, Abdelhai Abdelqader, Aditya Hendrani, Matthew J. Feinstein, Arman Qamar, Parag H. Joshi, Kristopher J. Swiger, Kathleen Byrne, Renato Quispe, Steven R. Jones, Roger S. Blumenthal, Seth S. Martin

Research output: Contribution to journalReview article

5 Citations (Scopus)

Abstract

In this review, we examine alirocumab (Praluent®), a monoclonal antibody to PCSK9 and its role in reducing LDL-C levels. By comparing the results of various studies and trials we discuss the efficacy and safety of alirocumab. We aim to guide clinicians of the role of alirocumab in clinical practice. Overall, PCSK9 inhibitors are promising new agents in further reducing LDL-C levels in addition to diet and maximally tolerated statin therapy. Long-term outcome studies are currently ongoing and will further delineate the role of PCSK9 inhibitors.

Original languageEnglish (US)
Pages (from-to)149-157
Number of pages9
JournalFuture Cardiology
Volume12
Issue number2
DOIs
StatePublished - Mar 1 2016

Fingerprint

LDL Cholesterol
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Monoclonal Antibodies
Outcome Assessment (Health Care)
Diet
Safety
alirocumab
Therapeutics

Keywords

  • alirocumab
  • evolocumab
  • LDL
  • monoclonal antibodies
  • PCSK9 inhibitors
  • statin intolerance

ASJC Scopus subject areas

  • Molecular Medicine
  • Cardiology and Cardiovascular Medicine

Cite this

Dahagam, C., Goud, A., Abdelqader, A., Hendrani, A., Feinstein, M. J., Qamar, A., ... Martin, S. S. (2016). PCSK9 inhibitors and their role in high-risk patients in reducing LDL cholesterol levels: Alirocumab. Future Cardiology, 12(2), 149-157. https://doi.org/10.2217/fca.15.88

PCSK9 inhibitors and their role in high-risk patients in reducing LDL cholesterol levels : Alirocumab. / Dahagam, Chanukya; Goud, Aditya; Abdelqader, Abdelhai; Hendrani, Aditya; Feinstein, Matthew J.; Qamar, Arman; Joshi, Parag H.; Swiger, Kristopher J.; Byrne, Kathleen; Quispe, Renato; Jones, Steven R.; Blumenthal, Roger S.; Martin, Seth S.

In: Future Cardiology, Vol. 12, No. 2, 01.03.2016, p. 149-157.

Research output: Contribution to journalReview article

Dahagam, C, Goud, A, Abdelqader, A, Hendrani, A, Feinstein, MJ, Qamar, A, Joshi, PH, Swiger, KJ, Byrne, K, Quispe, R, Jones, SR, Blumenthal, RS & Martin, SS 2016, 'PCSK9 inhibitors and their role in high-risk patients in reducing LDL cholesterol levels: Alirocumab', Future Cardiology, vol. 12, no. 2, pp. 149-157. https://doi.org/10.2217/fca.15.88
Dahagam C, Goud A, Abdelqader A, Hendrani A, Feinstein MJ, Qamar A et al. PCSK9 inhibitors and their role in high-risk patients in reducing LDL cholesterol levels: Alirocumab. Future Cardiology. 2016 Mar 1;12(2):149-157. https://doi.org/10.2217/fca.15.88
Dahagam, Chanukya ; Goud, Aditya ; Abdelqader, Abdelhai ; Hendrani, Aditya ; Feinstein, Matthew J. ; Qamar, Arman ; Joshi, Parag H. ; Swiger, Kristopher J. ; Byrne, Kathleen ; Quispe, Renato ; Jones, Steven R. ; Blumenthal, Roger S. ; Martin, Seth S. / PCSK9 inhibitors and their role in high-risk patients in reducing LDL cholesterol levels : Alirocumab. In: Future Cardiology. 2016 ; Vol. 12, No. 2. pp. 149-157.
@article{dd0be423b3d845759fc3f4340c6fdfdb,
title = "PCSK9 inhibitors and their role in high-risk patients in reducing LDL cholesterol levels: Alirocumab",
abstract = "In this review, we examine alirocumab (Praluent{\circledR}), a monoclonal antibody to PCSK9 and its role in reducing LDL-C levels. By comparing the results of various studies and trials we discuss the efficacy and safety of alirocumab. We aim to guide clinicians of the role of alirocumab in clinical practice. Overall, PCSK9 inhibitors are promising new agents in further reducing LDL-C levels in addition to diet and maximally tolerated statin therapy. Long-term outcome studies are currently ongoing and will further delineate the role of PCSK9 inhibitors.",
keywords = "alirocumab, evolocumab, LDL, monoclonal antibodies, PCSK9 inhibitors, statin intolerance",
author = "Chanukya Dahagam and Aditya Goud and Abdelhai Abdelqader and Aditya Hendrani and Feinstein, {Matthew J.} and Arman Qamar and Joshi, {Parag H.} and Swiger, {Kristopher J.} and Kathleen Byrne and Renato Quispe and Jones, {Steven R.} and Blumenthal, {Roger S.} and Martin, {Seth S.}",
year = "2016",
month = "3",
day = "1",
doi = "10.2217/fca.15.88",
language = "English (US)",
volume = "12",
pages = "149--157",
journal = "Future Cardiology",
issn = "1479-6678",
publisher = "Future Medicine Ltd.",
number = "2",

}

TY - JOUR

T1 - PCSK9 inhibitors and their role in high-risk patients in reducing LDL cholesterol levels

T2 - Alirocumab

AU - Dahagam, Chanukya

AU - Goud, Aditya

AU - Abdelqader, Abdelhai

AU - Hendrani, Aditya

AU - Feinstein, Matthew J.

AU - Qamar, Arman

AU - Joshi, Parag H.

AU - Swiger, Kristopher J.

AU - Byrne, Kathleen

AU - Quispe, Renato

AU - Jones, Steven R.

AU - Blumenthal, Roger S.

AU - Martin, Seth S.

PY - 2016/3/1

Y1 - 2016/3/1

N2 - In this review, we examine alirocumab (Praluent®), a monoclonal antibody to PCSK9 and its role in reducing LDL-C levels. By comparing the results of various studies and trials we discuss the efficacy and safety of alirocumab. We aim to guide clinicians of the role of alirocumab in clinical practice. Overall, PCSK9 inhibitors are promising new agents in further reducing LDL-C levels in addition to diet and maximally tolerated statin therapy. Long-term outcome studies are currently ongoing and will further delineate the role of PCSK9 inhibitors.

AB - In this review, we examine alirocumab (Praluent®), a monoclonal antibody to PCSK9 and its role in reducing LDL-C levels. By comparing the results of various studies and trials we discuss the efficacy and safety of alirocumab. We aim to guide clinicians of the role of alirocumab in clinical practice. Overall, PCSK9 inhibitors are promising new agents in further reducing LDL-C levels in addition to diet and maximally tolerated statin therapy. Long-term outcome studies are currently ongoing and will further delineate the role of PCSK9 inhibitors.

KW - alirocumab

KW - evolocumab

KW - LDL

KW - monoclonal antibodies

KW - PCSK9 inhibitors

KW - statin intolerance

UR - http://www.scopus.com/inward/record.url?scp=84959908518&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959908518&partnerID=8YFLogxK

U2 - 10.2217/fca.15.88

DO - 10.2217/fca.15.88

M3 - Review article

C2 - 26911710

AN - SCOPUS:84959908518

VL - 12

SP - 149

EP - 157

JO - Future Cardiology

JF - Future Cardiology

SN - 1479-6678

IS - 2

ER -